- Email: [email protected]
PON1 activity in patients with cardiovascular disease
Abstracts / Toxicology Letters 259S (2016) S73–S247
PP9.6 Arsenic metabolism profile in an adult population environmentally co-exposed to fluoride and moderate level of arsenic ˜ 1 , T. Matousek 2 , E. M.I. Jiménez-Córdova 1 , L.C. Sánchez-Pena Villarreal 3 , M. Cárdenas-González 1 , A. Barrera-Hernández 1 , M.C. González-Horta 3 , O.C. Barbier 1 , L.M. Del Razo 1 1
Toxicología, Cinvestav-IPN, Mexico City, Mexico Institute of Analytical Chemistry of the ASCR, Czech Republic 3 Facultad de Ciencias Químicas, Universidad Autónoma de Chihuahua, Chihuahua, Mexico 2
Introduction: Inorganic arsenic (iAs) and fluoride (F− ) are the two major environmental toxicants in drinking water. Studies have shown that the iAs metabolism is determinant of its toxic effects, and experimental data suggest that F− can inhibit the activity of several enzymes. The concomitant exposure to iAs and F− is common. However, the information about the effect of their coexposure is limited and controversial. Objective: The aim of this study was to evaluate the relationship between F− exposure and the arsenic metabolism profile in an adult population when levels of As in drinking water are lower than 55 g/L. Material and methods: A cross-sectional study was conducted in 239 adults (18–77 years old) residents of three municipalities of Chihuahua, Mexico who drank water containing 0.07–4.28 mgF− /L and 0.01–54.3 gAs/L. Concentration of F− was assessed by potentiometry, using an F− ion-selective electrode. Concentrations of iAs and its metabolites (MAs and DMAs) were assessed by hydride generation-cryotrapping-atomic absorption spectrometry. Results: Our results showed a positive correlation between urinary F− and total speciated As in urine concentrations (r = 0.85, p < 0.0001), which were ranged in 0.34–22.7 g/mL and 2.68–190.58 ng/mL, respectively. The multiple regression analysis showed a positive association between urinary F− and the relative proportions of iAs and MAs, accompanied by negative association between F− exposure and DMAs proportion in urine. Conclusions: These results suggest that F− exposure alters iAs methylation and may affect the toxicity related to iAs exposure. Financial support: This study was supported by Conacyt SSA/IMSS/ISSSTE 180847 and Conacyt bilateral cooperation 204276. http://dx.doi.org/10.1016/j.toxlet.2016.07.310
S121
Objective: To evaluate the relationship between PON1 activity (CMPase activity) and some lifestyle factors in patients with a cardiovascular disease. Materials and methods: A transversal, descriptive, and analytical study was conducted in 49 patients referred with chronic ischemic disease. This study was approved by the Institutional Ethics Committee, Nayarit, Mexico. The purpose and procedures of the study were explained to all of the participants, and a signed informed consent was obtained from each participant. The participants received questionnaires to gather information regarding their sociodemographic and anthropometric characteristics, and others. Blood samples were obtained to evaluate clinical parameters and PON1 activity measured in plasma (4-[chloromethyl] phenyl acetate as substrate). Results: The anthropometric characteristics of the study population showed an average age of 64.6 years. The study group consisted of 79.6% males and 20.4% females. The patients’ Body Mass Index was 28.2, according to World Health Organization criteria, 44.9% of the population was overweight, and 34.69% obese. The clinical history showed that 77.5% are dyslipidemic and hypertensive and 42.9% are diabetics. Regarding harmful habits, 8.2% are smokers and 28.6% consume alcohol. Regarding PON1 activity, the average was 14.43 U/L, with the lowest activity at 5 U/L and the highest activity at 30 U/L. It was also found that one half of patients had lower activity than the average. Conclusions: These preliminary results showed that PON1 activity (CMPA hydrolysis) was low in one half of the patients. This might suggest that the quality of the PON1 enzyme is an important factor in cardiovascular diseases in this study population. However, more studies are required to establish a relationship between PON1 activities and a cardiovascular risk. Financial support: This work was support by CONACyT grant 233745 and Pesticide Toxicology Network (Conacyt253789/271775). http://dx.doi.org/10.1016/j.toxlet.2016.07.311 PP9.8 Chronic ischemic patients and paraoxonase activity N. Ponce-Ruiz 1,3 , F.E. Murillo-González 1,3 , J. Ponce-Gallegos 2 , M.C. Xotlanihua-Gervacio 1,3 , A.E. Rojas-García 3 , B.S. Barrón-Vivanco 3 , Y.Y. Bernal-Hernández 3 , C.A. González-Arias 3 , I.M. Medina-Díaz 3 1
Posgrado CBAP, Nayarit, Mexico IMSS, Nayarit, Mexico 3 Universidad Autónoma de Nayarit, Nayarit, Mexico 2
PP9.7 PON1 activity in patients with cardiovascular disease F.E. Murillo-González 1,3 , N. Ponce-Ruíz 1,3 , M.C. Xotlanihua-Gervacio 1,3 , J. Ponce-Gallegos 2 , A.E. Rojas-García 3 , Y.Y. Bernal-Hernández 3 , B.S. Barrón-Vivanco 3 , I.M. Medina-Díaz 3 1
Posgrado CBAP, Nayarit, Mexico IMSS, Nayarit, Mexico 3 Universidad Autónoma de Nayarit, Nayarit, Mexico 2
Introduction: Serum paraoxonase 1 (PON1) is a high-density lipoprotein-associated enzyme capable of hydrolyzing a wide spectrum of substrates. Evidence indicates that the serum concentration of PON1 is related with plasma lipid and lipoprotein concentrations, and possibly with development of cardiovascular diseases.
Introduction: Paraoxonase 1 (PON1) is an A-esterase synthesized mainly in the liver and secreted into the serum, where it is associated with high-density lipoproteins (HDL). PON1 detoxifies a wide range of substrates including organophosphate compounds, lactones, and cyclic aromatic carboxylic aromatic compounds. PON1 prevents the formation of oxidized low-density lipoproteins, thus the development of atherosclerosis. Low PON1 activity has been linked with risk for major cardiovascular disease development. Objective: The aim of this study was to determine the PON activity (PONase) in chronic ischemic patients with cardiovascular disease. Materials and methods: A transversal, descriptive, and analytical study was conducted in 49 patients who referred chronic ischemic disease. This study was approved by the Institutional Ethics Committee (Hospital Antonio González Guevara, Tepic,
PP9.6 Arsenic metabolism profile in an adult population environmentally co-exposed to fluoride and moderate level of arsenic ˜ 1 , T. Matousek 2 , E. M.I. Jiménez-Córdova 1 , L.C. Sánchez-Pena Villarreal 3 , M. Cárdenas-González 1 , A. Barrera-Hernández 1 , M.C. González-Horta 3 , O.C. Barbier 1 , L.M. Del Razo 1 1
Toxicología, Cinvestav-IPN, Mexico City, Mexico Institute of Analytical Chemistry of the ASCR, Czech Republic 3 Facultad de Ciencias Químicas, Universidad Autónoma de Chihuahua, Chihuahua, Mexico 2
Introduction: Inorganic arsenic (iAs) and fluoride (F− ) are the two major environmental toxicants in drinking water. Studies have shown that the iAs metabolism is determinant of its toxic effects, and experimental data suggest that F− can inhibit the activity of several enzymes. The concomitant exposure to iAs and F− is common. However, the information about the effect of their coexposure is limited and controversial. Objective: The aim of this study was to evaluate the relationship between F− exposure and the arsenic metabolism profile in an adult population when levels of As in drinking water are lower than 55 g/L. Material and methods: A cross-sectional study was conducted in 239 adults (18–77 years old) residents of three municipalities of Chihuahua, Mexico who drank water containing 0.07–4.28 mgF− /L and 0.01–54.3 gAs/L. Concentration of F− was assessed by potentiometry, using an F− ion-selective electrode. Concentrations of iAs and its metabolites (MAs and DMAs) were assessed by hydride generation-cryotrapping-atomic absorption spectrometry. Results: Our results showed a positive correlation between urinary F− and total speciated As in urine concentrations (r = 0.85, p < 0.0001), which were ranged in 0.34–22.7 g/mL and 2.68–190.58 ng/mL, respectively. The multiple regression analysis showed a positive association between urinary F− and the relative proportions of iAs and MAs, accompanied by negative association between F− exposure and DMAs proportion in urine. Conclusions: These results suggest that F− exposure alters iAs methylation and may affect the toxicity related to iAs exposure. Financial support: This study was supported by Conacyt SSA/IMSS/ISSSTE 180847 and Conacyt bilateral cooperation 204276. http://dx.doi.org/10.1016/j.toxlet.2016.07.310
S121
Objective: To evaluate the relationship between PON1 activity (CMPase activity) and some lifestyle factors in patients with a cardiovascular disease. Materials and methods: A transversal, descriptive, and analytical study was conducted in 49 patients referred with chronic ischemic disease. This study was approved by the Institutional Ethics Committee, Nayarit, Mexico. The purpose and procedures of the study were explained to all of the participants, and a signed informed consent was obtained from each participant. The participants received questionnaires to gather information regarding their sociodemographic and anthropometric characteristics, and others. Blood samples were obtained to evaluate clinical parameters and PON1 activity measured in plasma (4-[chloromethyl] phenyl acetate as substrate). Results: The anthropometric characteristics of the study population showed an average age of 64.6 years. The study group consisted of 79.6% males and 20.4% females. The patients’ Body Mass Index was 28.2, according to World Health Organization criteria, 44.9% of the population was overweight, and 34.69% obese. The clinical history showed that 77.5% are dyslipidemic and hypertensive and 42.9% are diabetics. Regarding harmful habits, 8.2% are smokers and 28.6% consume alcohol. Regarding PON1 activity, the average was 14.43 U/L, with the lowest activity at 5 U/L and the highest activity at 30 U/L. It was also found that one half of patients had lower activity than the average. Conclusions: These preliminary results showed that PON1 activity (CMPA hydrolysis) was low in one half of the patients. This might suggest that the quality of the PON1 enzyme is an important factor in cardiovascular diseases in this study population. However, more studies are required to establish a relationship between PON1 activities and a cardiovascular risk. Financial support: This work was support by CONACyT grant 233745 and Pesticide Toxicology Network (Conacyt253789/271775). http://dx.doi.org/10.1016/j.toxlet.2016.07.311 PP9.8 Chronic ischemic patients and paraoxonase activity N. Ponce-Ruiz 1,3 , F.E. Murillo-González 1,3 , J. Ponce-Gallegos 2 , M.C. Xotlanihua-Gervacio 1,3 , A.E. Rojas-García 3 , B.S. Barrón-Vivanco 3 , Y.Y. Bernal-Hernández 3 , C.A. González-Arias 3 , I.M. Medina-Díaz 3 1
Posgrado CBAP, Nayarit, Mexico IMSS, Nayarit, Mexico 3 Universidad Autónoma de Nayarit, Nayarit, Mexico 2
PP9.7 PON1 activity in patients with cardiovascular disease F.E. Murillo-González 1,3 , N. Ponce-Ruíz 1,3 , M.C. Xotlanihua-Gervacio 1,3 , J. Ponce-Gallegos 2 , A.E. Rojas-García 3 , Y.Y. Bernal-Hernández 3 , B.S. Barrón-Vivanco 3 , I.M. Medina-Díaz 3 1
Posgrado CBAP, Nayarit, Mexico IMSS, Nayarit, Mexico 3 Universidad Autónoma de Nayarit, Nayarit, Mexico 2
Introduction: Serum paraoxonase 1 (PON1) is a high-density lipoprotein-associated enzyme capable of hydrolyzing a wide spectrum of substrates. Evidence indicates that the serum concentration of PON1 is related with plasma lipid and lipoprotein concentrations, and possibly with development of cardiovascular diseases.
Introduction: Paraoxonase 1 (PON1) is an A-esterase synthesized mainly in the liver and secreted into the serum, where it is associated with high-density lipoproteins (HDL). PON1 detoxifies a wide range of substrates including organophosphate compounds, lactones, and cyclic aromatic carboxylic aromatic compounds. PON1 prevents the formation of oxidized low-density lipoproteins, thus the development of atherosclerosis. Low PON1 activity has been linked with risk for major cardiovascular disease development. Objective: The aim of this study was to determine the PON activity (PONase) in chronic ischemic patients with cardiovascular disease. Materials and methods: A transversal, descriptive, and analytical study was conducted in 49 patients who referred chronic ischemic disease. This study was approved by the Institutional Ethics Committee (Hospital Antonio González Guevara, Tepic,